The efficacy and safety of biologic or targeted synthetic DMARDs in rheumatoid arthritis treatment: one year of review 2024

Abstract

Background: Both articular and extra-articular structures are affected by rheumatoid arthritis (RA), a chronic inflammatory rheumatic illness that results in severe joint destruction, disability, and death. To increase the response rate and provide RA patients more options, there is an unmet need for the development of innovative treatment drugs. Evaluation of cellular, cytokine, genomic, and transcriptome profiles that would predict therapeutic response to biologic or targeted disease-modifying anti-rheumatic drugs (DMARDs) with various action modes is necessary for a customized therapy plan in RA. Owing to the development of new biologic medicines that target distinct mechanisms of action, the treatment algorithm for RA has undergone significant modification during the last one to two decades. More patients are now able to undergo biologic therapy early in the progression of their illness, thanks to the availability of less expensive biosimilars. Objective: To summarize the efficacy and safety of biologic or targeted syntheticb/ts DMARDs in RA treatment based on the publications in the past year. Material and Methods: We compiled the most recent findings from original research publications of 2024 about the effects of b/tsDMARDs on the treatment of RA. In addition, this review article also concluded the recent findings from original research publications of the year 2024 about the effects of b/tsDMARDs biosimilars for treating RA. Conclusion: This article summarizes the evidence and safety of biologic DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs) in the management of RA, including those that target tumor necrosis factor alpha, interleukin (IL)-6, B cells, T-cell co-stimulation, and Janus kinase (JAK) from original research articles published in 2024.